UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET
Company Participants
Vincent Perrone - Senior Director-Investor Relations
Liz Barrett - President & Chief Executive Officer
Mark Schoenberg - Chief Medical Officer
Jeff Bova - Chief Commercial Officer
Don Kim - Chief Financial Officer
Conference Call Participants
Dipesh Patel - H.C. Wainwright
Boris Peaker - Cowen
Matt Kaplan - Ladenburg
Chris Howerton - Jefferies
Paul Choi - Goldman Sachs
Leland Gershell - Oppenheimer
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's Third Quarter 2022 Financial Results and Business Update Conference Call.
It is now my pleasure to turn the call over to Vincent Perrone, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.
Vincent Perrone
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2022 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2022. The press release can be accessed on the Investors portion of our website at investors.urogen.com.
Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities relating to Jelmyto, the expected benefits of the FDA's expansion of the end-use period for Jelmyto, our ongoing and planned clinical trials, commercial and clinical milestones in the year ahead, the growth potential for Jelmyto, the design potential benefits and commercial potential for UGN-102, if approved, the design, potential benefits and commercial potential of UGN-301, potential future commercialization activities for UGN-102 if approved, data presentations, expected regulatory filings and timing thereof, future research and development efforts and our financial and other corporate goals, among other things.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and leave its SEC disclosure documents, including under the Risk Factors heading of our quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed today. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements.